MTAP, the Myozyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More) Temporary Access Program, is a clinical program to provide access to MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More produced by a

As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing

2006 AMDA/IPA Conference Report By Allan Muir With contributions from George Fox and Jared Salbato Friday—November 17, 2006 Texas Hoe

Pompe Workshop Report Allan Muir, Pompe Representative, AGSD(UK) On October the 16th this year we held our annual AGSD (UK)

Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation in the

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More)

Product is First Treatment for Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More Genzyme Corp. (Nasdaq: GENZ) announced today that it has received marketing authorization for

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the review period

The IPA has developed the Pompe connections brochure to help get patients and their families timely and relevant information about

Genzyme Corp. (Nasdaq: GENZ) announced today that it has submitted a biologics license application (BLA) to the U.S. Food and